| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1010.)
© 2004 American Heart Association, Inc.
Emerging Therapies |
From Helsinki University Central Hospital, Helsinki, Finland (T.E.); University of Texas Health Science Center at San Antonio and A. Murphy Veterans Administration Hospital, San Antonio, Tex (G.R.); Alzheimers Disease Research Unit, McGill Centre for Studies on Aging, Montreal, Quebec, Canada (S.G.); Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada (H.F.); and Queen Elizabeth II Health Science Centre, Geriatric Medicine Research Unit, Dalhousie University, Halifax, Nova Scotia, Canada (K.R.).
Reprint requests to Dr Gustavo Román, University of Texas Health Science Center at San Antonio, Medicine/Neurology, Mail Code 7883, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900. E-mail romang{at}uthscsa.edu
Abstract
Background Cerebrovascular disease (CVD) and ischemic brain injury secondary to cardiovascular disease are common causes of dementia and cognitive decline in the elderly. CVD also contributes to cognitive loss in Alzheimer disease (AD).
Summary Progress in understanding vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in promising symptomatic and preventive treatments. Cholinergic deficits in VaD due to ischemia of basal forebrain nuclei and cholinergic pathways can be treated with cholinesterase inhibitors used in AD. Controlled clinical trials with donepezil and galantamine in patients with VaD, as well as in patients with AD plus CVD, have demonstrated improvement in cognition, behavior, and activities of daily living. The N-methyl-D-aspartate receptor antagonist memantine stabilized progression of VaD compared with placebo. Primary and secondary stroke prevention, in particular with control of hypertension and hyperlipidemia, can decrease VaD incidence.
Conclusions From a public health viewpoint, recognition of VCI before the development of dementia and correction of vascular burden on the brain may lead to a global decrease of incident dementia.
Key Words: carbamates cognitive disorders dementia galantamine memantine nimodipine piperidines vascular diseases donepezil rivastigmine
This article has been cited by other articles:
![]() |
J. S. Keverne, W. C. R. Low, I. Ziabreva, J. A. Court, A. E. Oakley, and R. N. Kalaria Cholinergic Neuronal Deficits in CADASIL Stroke, January 1, 2007; 38(1): 188 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, V. A. Magnotta, K. Duff, L. L. Boles Ponto, and S. K. Schultz Donepezil Effects on Cerebral Blood Flow in Older Adults With Mild Cognitive Deficits J Neuropsychiatry Clin Neurosci, May 1, 2006; 18(2): 178 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Edwards, M. G. Hahn, C. M. Baum, M. S. Perlmutter, C. Sheedy, and A. W. Dromerick Screening Patients with Stroke for Rehabilitation Needs: Validation of the Post-Stroke Rehabilitation Guidelines Neurorehabil Neural Repair, March 1, 2006; 20(1): 42 - 48. [Abstract] [PDF] |
||||
![]() |
R Overshott and A Burns Treatment of dementia J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(suppl_5): v53 - v59. [Full Text] [PDF] |
||||
![]() |
B. C. Dickerson, D. Holtzman, P. E. Grant, and D. Tian Case 36-2005 -- A 61-Year-Old Woman with Seizure, Disturbed Gait, and Altered Mental Status. N. Engl. J. Med., November 24, 2005; 353(21): 2271 - 2280. [Full Text] [PDF] |
||||
![]() |
S. Moriguchi, X. Zhao, W. Marszalec, J. Z. Yeh, and T. Narahashi Modulation of N-Methyl-D-aspartate Receptors by Donepezil in Rat Cortical Neurons J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 125 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Overshott and A. Burns Cholinesterase inhibitors: in search of cholinergic deficits Advan. Psychiatr. Treat., September 1, 2005; 11(5): 321 - 324. [Full Text] [PDF] |
||||
![]() |
L. H. Kuller, O. L. Lopez, W. J. Jagust, J. T. Becker, S. T. DeKosky, C. Lyketsos, C. Kawas, J.C.S. Breitner, A. Fitzpatrick, and C. Dulberg Determinants of vascular dementia in the Cardiovascular Health Cognition Study Neurology, May 10, 2005; 64(9): 1548 - 1552. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shibata, R. Ohtani, M. Ihara, and H. Tomimoto White Matter Lesions and Glial Activation in a Novel Mouse Model of Chronic Cerebral Hypoperfusion Stroke, November 1, 2004; 35(11): 2598 - 2603. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |